Pre-competitive development of chemical probes for epigenetic targets: a novel paradigm.

A team of academic and industry researchers will create 25 small molecule chemical probes that can precisely switch off specific epigenetic proteins in cells. Epigenetics controls which genes are switched on or off without changing the DNA sequence itself. Faults in this system drive major diseases including cancer, metabolic disorders, and neurodegeneration. But researchers currently lack the tools to cleanly test which epigenetic proteins cause which effects. Existing probes are often too weak or hit multiple targets, producing muddy results. This project aims to fill that gap by engineering probes with pre-defined potency, selectivity, and cellular activity against three protein families: histone lysine demethylases, bromodomains, and tudor domains. If successful, the probes will be made freely available to the global scientific community. This could transform how labs dissect epigenetic signalling, allowing them to link specific proteins to specific disease mechanisms with confidence. Better probes mean cleaner experiments, which in turn could accelerate the discovery of drug targets for cancer, metabolic disease, and neurodegeneration. The work is applied fundamental science—it does not deliver a therapy directly, but it builds the essential toolkit that makes targeted drug discovery possible.